PubMed Health⌕ Search

Biomedical subjects

R G Sibbald

Publications and source records attributed to R G Sibbald.

At least 37 records · Page 2Linked to original sources
PubMed1998

Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.

BACKGROUND: Topical corticosteroids are often used in the treatment of psoriasis, but long-term use may be associated with serious adverse events such as tachyphylaxis or atrophy of the skin. Tazarotene, a new topical retinoid, has demonstrated significant clinical benefits but can cause mild to moderate local irritation. OBJECTIVE: We evaluate whether a combination treatment of topical tazarotene and a topical corticosteroid would increase efficacy while reducing the incidence of local adverse events associated with a topical retinoid. METHODS: Three hundred patients enrolled in an investigator-masked study were randomly assigned to 1 of 4 treatment groups: tazarotene 0.1% gel in combination with placebo cream, or with a low-, mid-, or high-potency corticosteroid cream, for 12 weeks of treatment and a posttreatment follow-up at week 16. RESULTS: Tazarotene 0.1% gel in combination with a mid- or high-potency corticosteroid, when compared with tazarotene plus placebo cream, achieved significantly greater reductions in scaling, erythema, and overall lesional severity, and a decreased incidence of adverse events. CONCLUSION: All tazarotene combinations (including tazarotene plus placebo) were highly effective in rapidly reducing the severity of psoriasis. Combining tazarotene with a topical corticosteroid increased efficacy while reducing the incidence of local adverse events.

Administration, Cutaneous↗
PubMed1998

A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes.

A randomized, double-blind, clinic-initiated, sequential dose-escalation pilot study was performed to compare the safety and efficacy of single applications of 1, 3, and 5% cidofovir gel with placebo in the treatment of early, lesional, recurrent genital herpes at five Canadian outpatient sites. Ninety-six patients began treatment within 12 h of lesion appearance and were evaluated twice daily until healing of the lesion occurred. Cidofovir gel at all strengths significantly decreased the median time to negative virus culture in a dose-dependent fashion (3.0 days in the placebo group versus 2.2, 1.3, and 1.1 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively; P = 0.02, 0.0001, and 0.0003, respectively). A trend toward a reduction in the median time to complete healing in association with treatment was present, but the differences were not statistically significant (5.0 days in the placebo group versus 4.3, 4.1, and 4.6 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively). Application site reactions occurred in 3, 5, 19, and 22% of the patients in these four groups, respectively. Treatment-associated lesion recrudescence with delayed healing, which is suggestive of local toxicity, was observed in three patients treated with 5% cidofovir gel and one patient treated with 3% cidofovir gel. In summary, single-dose application of cidofovir gel confers a significant antiviral effect on lesions of recurrent genital herpes. Additional studies are warranted to further identify the optimal efficacious dose of cidofovir in association with the maximum gel strength that can be tolerated.

Adult↗
PubMed1998

Mentoring: the ultimate professional relationship.

Mentoring plays a significant role in business, industry, government, education, and healthcare. Mentoring relationships help promote the individual's professional growth and development. Such development involves knowledge and skill acquisition, which is facilitated by interaction with other, more experienced and proficient professionals. The Belcher-Sibbald Continuum of Learning describes the relationship among the concepts of role modeling, networking, preceptoring, and mentoring. Each concept is defined and described as a unique relationship which promotes professional growth and development. In addition, three mentoring/networking relationships in the context of the wound care community are presented to provide insight into this type of relationship.

Humans↗
PubMed1998

Hand eczema.

Hand eczema is a common disorder of healthcare providers. The pattern of eczema can help to distinguish endogenous (dyshidrosis, atopy) causes from exogenous (contact irritant and allergic dermatitis) and the common differential diagnoses (psoriasis, fungus infections). Appropriate strength topical steroids, moisturizers, antibacterials, and systemic agents are all used to treat hand eczema depending on the type of eczema and its severity. Patients with contact allergic eczema should be assessed for possible latex allergy.

Adult↗
PubMed1998

An approach to leg and foot ulcers: a brief overview.

Legs and feet are susceptible to ulcer formation. Three main types of lower extremity ulcers are venous, arterial, and neurotropic. Ulcer care should include treatment of the underlying cause, moist interactive healing, and quality of life (pain control). If the ulcer shows no signs of healing in 6 to 12 weeks, the wound should be biopsied, the diagnosis confirmed, and a plan of care instituted. In certain instances, biologicals may be used. A graphical representation of an approach to ulcer care, in addition to common differential diagnoses of leg ulcers, is presented.

Algorithms↗
PubMed1998

Venous leg ulcers.

Venous ulcers are the most common form of leg ulcers and their incidence is increasing as the population ages. The diagnosis should be confirmed with tests for venous insufficiency and an assessment of arterial disease determined by a Doppler Ankle-Brachial ratio. The most important component of venous ulcer treatment is the use of high compression bandages for pitting edema. Non-healing ulcers may require a skin biopsy of the edge to confirm the diagnosis, medical treatment for woody fibrosis, adjustment of compression therapy, or use of a skin substitute or biological preparation.

Bandages↗
PubMed1997

Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis.

Adverse effects may occur in 10.4% of patients receiving terbinafine therapy, with cutaneous reactions in 2.7%. We describe the development of psoriasis in four patients who took oral terbinafine. Two patients had plaque-type psoriasis that flared 12 and 17 days, respectively, after starting terbinafine. Another patient developed pustular-type psoriasis de novo after 27 days of terbinafine therapy. The fourth patient was a psoriatic with stable plaque disease who experienced a pustular flare after taking terbinafine for 21 days. We are aware of only one report in the literature in which a patient developed pustular psoriasis de novo after 5 days of terbinafine therapy. In all patients the psoriasis cleared or lessened after discontinuation of terbinafine and institution of antipsoriatic therapy.

Adult↗
PubMed1997

Onychomycosis in children: prevalence and treatment strategies.

BACKGROUND: Onychomycosis is observed less frequently in children than adults. Until recently management of onychomycosis in children included topical formulations, oral griseofulvin, and in some cases deferral of treatment. OBJECTIVE: We attempted to determine the prevalence of onychomycosis in North American children 18 years old or younger attending our dermatology offices (three Canadian, two U.S.) and to report the group's experience using fluconazole, itraconazole, and terbinafine for onychomycosis. METHODS: We undertook a prospective, multicenter survey in which all children, regardless of presenting complaint, were examined for onychomycosis by a dermatologist. In instances of clinical suspicion appropriate nail samples were obtained for light microscopy and culture. RESULTS: A total of 2500 children under age 18 were examined in the five-center survey (1117 males and 1383 females, mean +/- S.E. age: 11.2 +/- 0.1 years). There was one child with fingernail and ten with mycologically confirmed toenail dermatophyte onychomycosis. The overall prevalence of onychomycosis was 0.44%. Considering those children whose primary or referring diagnosis was not onychomycosis or tinea pedis, the prevalence of onychomycosis was 0.16%. Outside the survey we have seen six other children with dermatophyte onychomycosis; these 17 cases form the basis for the remainder of the report. Of the 17 children, eight (47%) had concomitant tinea pedis infection, and in 11 (65%) a sibling, parent, or grandparent had onychomycosis or tinea pedis. Management included topical terbinafine (two patients: one cured, one failed therapy), topical ketoconazole (one patient: clinical improvement), oral fluconazole (two patients: one cured, one had Down's syndrome and was noncompliant), oral itraconazole (four patients: three cured with subsequent recurrence at follow-up in one patient, one lost to follow-up), oral terbinafine (five patients: four cured with subsequent recurrence at follow-up in one patient, one failed therapy). One child received no therapy following discussion with the parents, one was lost to follow-up and one was found to have asymptomatic hepatic dysfunction with hepatitis C at pretherapy bloodwork. CONCLUSION: The prevalence of onychomycosis in our sample of North American children 18 years old or younger was 0.44% (n = 2500). In the subset of children whose primary or referring diagnosis was not onychomycosis, the prevalence of onychomycosis was 0.16%. Children with onychomycosis should be carefully examined for concomitant tinea pedis, and their parents and siblings checked for onychomycosis and tinea pedis. The newer oral antifungal agents fluconazole, itraconazole, and terbinafine may be effective and well-tolerated in the treatment of onychomycosis in this age group. These drugs should be carefully evaluated in a larger cohort of children with onychomycosis.

Adolescent↗
PubMed1997

A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study.

There is some controversy about the prevalence of onychomycosis in patients with psoriasis compared to non-psoriatics. We therefore measured the prevalence of toenail onychomycosis in psoriatics and non-psoriatics attending dermatologists' offices. None of the patients had a referring diagnosis of onychomycosis. The prevalence of pedal onychomycosis in psoriatics (n = 561) was 13%. The odds of patients with psoriasis having onychomycosis was 56% greater than non-psoriatics of the same age and sex (P = 0.02). In the psoriatics, when the toenails were clinically abnormal, the prevalence of onychomycosis was 27%. The odds of developing onychomycosis increased with age (P < 0.0001) and the odds of men developing onychomycosis was 2.5 times that of women (P = 0.0001). The duration of psoriasis did not significantly affect the odds of developing onychomycosis. The fungal organisms recovered from psoriasis subjects with onychomycosis were similar to those in the normal population with onychomycosis (P = 0.58).

Female↗
PubMed1996

Eutectic lidocaine/prilocaine 5% cream and patch may provide satisfactory analgesia for excisional biopsy or curettage with electrosurgery of cutaneous lesions. A randomized, controlled, parallel group study.

BACKGROUND: Needle puncture and infiltrational anesthesia is generally required for minor cutaneous surgical procedures and may be associated with anxiety, fear, discomfort, and pain. The use of topical anesthetics such as eutectic lidocaine/prilocaine 5% cream may provide an alternative means of delivering anesthesia. OBJECTIVE: Our purpose was to evaluate the effectiveness of eutectic lidocaine/prilocaine 5% cream applied under either occlusive adhesive dressing (Tegaderm) or patch formulation in providing analgesia for removal of lesions 40 mm long or shorter on the trunk or extremities; removal was effected by excisional biopsy or curettage with electrosurgery. METHODS: One hundred six patients (58 men, 48 women), 22 to 90 years of age, participated in this open-labeled, randomized, controlled, parallel group study. Patients were randomly assigned to receive either 2.5 to 5 gm of cream applied under an occlusive dressing or a 1.0 gm single-dose-unit patch. The topical anesthetic was removed 2 to 3 hours after application and just before surgery. This area was then tested for analgesia to pinprick. If analgesia was insufficient to the pinprick or during the surgical procedure, lidocaine infiltration was given. Patients rated the pain of the surgical procedure on a 100 mm visual analog scale. RESULTS: After application times of 110 to 180 minutes, effective anesthesia was achieved in 87% of subjects. Treatment with the patch was equal to the cream/Tegaderm dressing in reducing pain experienced during surgery. No significant difference was found between the adhesiveness of the two dressings; however, the patch was easier to apply than the cream/ Tegaderm. No unexpected adverse events were observed. CONCLUSION: For minor skin surgical procedures involving excisional biopsy or curettage with electrosurgery, eutectic lidocaine/prilocaine 5% cream/Tegaderm and patch formulations were equally effective and provided effective anesthesia in 87% of subjects. The patch formulation may be more convenient for self-application.

Adhesiveness↗
PubMed1996

Skin and diabetes.

Skin manifestations associated with diabetes mellitus are common and, with close scrutiny, can occur in most, if not all, patients. Little information is available on what common pathophysiologic thread is responsible for the skin manifestation and diabetes. Although controlled studies are lacking, a recognition of the skin manifestations, treatment, and prognosis will help patients and their caregivers to understand treatment alternatives more clearly.

Adult↗
PubMed1993

Canadian dermatology.

Canadian dermatology differs from the American system by a predominant referral system in most provinces and by universal health care scheme. Canadian certification requires 1 year of internal medicine training in addition to 3 years of clinical training. The Canadian Dermatology Association has formed several links with the American Academy of Dermatology and sponsors a similar sun awareness campaign.

Canada↗